



Persistent congenital hyperinsulinemic hypoglycemia (CHH) 
can be caused by mutations in the ABCC8/KCNJ11, GLUD1, 
HADH, GCK, HNF4A, HNF1A, SLC16A1 and UCP2 genes (1,2). 
ABCC8/KCNJ11 mutations are most common (33-66%) and 
GLUD1 mutations are the second commonest cause of CHH, 
identified in approximately 5% of the cases. Mutations in other 
known genes (including HADH) together account for less than 
4% of CHH (1).
Loss of function mutations in the HADH (HADHSC, 
SCHAD) gene, causing short-chain L-3-hydroxyacyl-CoA 
(SCHAD) deficiency, were first reported to cause persistent 
CHH in 2001 (3). SCHAD catalyses the penultimate step in 
the mitochondrial fatty acid oxidation pathway, the NAD+-
dependent conversion of L-3-hydroxyacyl-CoA to 3-ketoacyl-
CoA (1). The main clinical feature of this metabolic disease 
is hypoketotic hypoglycemia with hyperinsulinism which is 
different from other inherited defects of fatty acid β-oxidation 
that can present with symptoms such as hepatomegaly, 
myopathy and cardiomyopathy. HADH mutations are 
recessively inherited and most of the reported cases are 
from consanguineous families. So far, approximately 40 
patients with CHH resulting from a mutation in the HADH 
gene have been reported (Table 1) (3,4,5,6,7,8,9,10,11,12, 
13,14,15).The mechanism behind unregulated insulin 
secretion in SCHAD deficiency is currently not understood 
but may involve changes in protein-protein interactions with 
glutamate dehydrogenase (GDH) (16,17).
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ABS TRACT
Unlike other congenital fatty acid oxidation defects, short-chain L-3-
hydroxyacyl-CoA (SCHAD, HADH) deficiency is characterised by hypoglycemia 
with hyperinsulinism in the neonatal or infancy periods. The long-term and 
detailed clinical progression of the disease is largely unknown with almost 
40 patients reported and only a few patients described clinically. We present 
clinical and laboratory findings together with the long-term clinical course of 
a case with a deep intronic HADH splicing mutation (c.636+471G>T) causing 
neonatal-onset hyperinsulinemic hypoglycemia with mild progression.
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The clinical presentation is mainly neonatal- or early 
infancy-onset HH and patients are diazoxide-responsive. It 
has also been shown that these patients have severe protein 
(especially leucine) sensitivity (10,16,17). Metabolic profiling in 
some, but not all, affected individuals reveals a raised plasma 
hydroxybutyrylcarnitine and urinary medium-chain dicarboxylic, 
3-hydroxydicarboxylic metabolites and 3-hydroxyglutarate 
levels.
Here we present the long-term follow-up of a case with a 
deep intronic HADH splicing mutation (c.636+471G>T) causing 
hyperinsulinemic hypoglycemia and review the reported cases 
so far.
Case Report
A 13.9-year-old girl was admitted to our hospital with 
complaints of headache and weakness. She had a convulsion 
attack with hypoglycemia one day before admission. Her 
medical history revealed that she had been diagnosed with 
persistent CHH at the age of 30 days following admission to a 
health center for generalised convulsion. She was born at term 
with a weight of 4000 g. Following the diagnosis of CHH, she 
was commenced on 10 mg/kg/day of diazoxide and remained 
on that dose for five years.
At the age of 2 years, the patient was lost to follow-
up for 5 years. Then, she presented at seven years of age 
with generalized convulsion with a hypoglycemic attack due 
to interrupted intake of medicine. After restarting diazoxide 
therapy (10 mg/kg/day) with regular intake, the girl did not have 
any hypoglycemic attacks but developed hypertrichosis.
At the age of 12.5 years, the patient was re-evaluated in 
another medical center. During hypoglycemia, her insulin level 
was detected to be very high (78.8 µIU/mL). Urinary amino 
acids and blood spot tandem mass were normal; there were 
no reducing substances in the urine. The results of a prolonged 
oral glucose tolerance test were normal. The diazoxide dose 
was tapered to 2.5 mg/kg/day slowly without episodes of 
hypoglycaemia. Drug cessation was tried but because of 
repeated hypoglycemic attacks diazoxide was started again at 
a dose of 2.5 mg/kg/day. When the girl was first admitted to 
our clinic after a hypoglycemic convulsion, she had complaints 
of headache and weakness, but physical examination was 
normal; height 153 cm (-0.93 SD) and weight 47 kg, body mass 
index (BMI) was 20.08 kg/m2. She was hospitalized for further 
evaluation. A fasting test was performed, but hypoglycemia 
was not detected during a 12-hour fast. While she was taking 
diazoxide 2 mg/kg/day, a non-ketotic hypoglycemic attack (blood 
glucose: 46 mg/dL) was detected with a very high insulin level 
(46.8 µIU/mL). During this episode, blood gas sampling, blood 
ammonia, cortisol and adrenocorticotropic hormone were all 
within the normal range.
Cranial MRI and an electroencephalogram did not reveal 
any pathology. Normoglycemia was maintained with diazoxide 
3 mg/kg/day. Genetic studies by Sanger sequencing did not 
reveal any mutations in the ABCC8, KCNJ11 or GLUD1 genes, 
however, sequencing of HADH identified a previously reported 
homozygous splicing mutation within intron 5 (c.636+471G>T) 
(Figure 1) (10). The parents who are not known to be 
consanguineous were both heterozygous for the mutation. 
The patient is currently 20 years of age and in good health. 
Table 1. Reported patients with hyperinsulinemic hypoglycemia having 
mutations in the HADH gene
Mutations References
p.P258L (c.773C>T) Clayton et al (3)
p.? (c.547-3_549del)  Molven et al (8) (n=2)
p.? (c.710-2A>G) Hussain et al (9)
p.M188V (c.562A>G) Kapoor et al (10)
p.R236X (c.706C>T)
DiCandia et al (13) 
Flanagan et al (5) (n=6)
Sogno Valin S et al (12)
p.S196fs (c.587del)    Martins et al (4) (n=3)
p.? (c.261+1G>A) Martins et al (4) 
Not available Kapoor et al (6) (n=3)
p.K136E (406A>G) Flanagan et al (5)
p.Q163X (c.487C>T) Flanagan et al (5)
p.K95fs (c.283_293delinsT)/
p.? (c.709+ 39C>G)
Flanagan et al (5)
Snider et al (7) (n=2)
p.? (c.1-3440_132+1943del) Flanagan et al (5) (n=2)
p.G34A (c.100 G>C) Snider et al (7)
p.T189fs (c.565del) Popa FI et al (14)
p.? (c.636+471G>T) Flanagan et al (11) (n=8)
Figure 1. Electropherogram showing the homozygous c.636+471G>T 
cryptic splicing mutation in intron 5 of the HADH gene (lower panel). A 
sequence trace for a control (upper panel) 
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Mental status and neurological examination were normal at 
her last follow-up visit. She was reported to have maintained 
her academic performance at the higher education institution 
she was attending. Her blood glucose levels continued to be at 
normal levels with the low dose (2-3 mg/kg/day) of diazoxide 
she has been receiving. She has reached her final height which 
is within normal ranges and has a BMI of 24.8 kg/m2. 
Informed consent was given by the patient.
Discussion
Recessive mutations in the HADH gene were first described 
by Clayton et al (3) in a four-month-old infant with hypoketotic 
hypoglycemia, inappropriately elevated insulin levels and 
elevated blood spot hydroxybutyrylcarnitine concentration. 
Since then, another 36 patients have been reported with HADH 
mutations (4,5,6,7,8,9,10,11,12,13,14). The clinical presentation 
of CHH due to HADH mutations is heterogeneous with some 
patients presenting with severe neonatal hypoglycemia and 
others - with mild infancy-onset hypoglycemia. Our case was 
born at term with a weight of 4000 g (1.63 SD) and presented 
with neonatal hypoglycemic seizure at the age of 30 days. Birth 
weight of patients with HADH gene mutation were usually 
reported as normal from 2730 g to 4350 g (3,4,5,6,7,8,9,10,11,
12,13,14,15). Early admitted patients usually had hypoglycemic 
seizure as our case (3,4,5,8,9,10,13,14,15). Martins et al (4) 
reported four new cases and reviewed seven reported cases 
with HH due to HADH deficiency. They found that patients 
became symptomatic in early life (ranging from 1.5 hours to 
8 months) and presented with hypoglycemic convulsions, 
lethargy and hypotonia. Although their symptoms had begun 
in infancy, three of the four new cases were diagnosed late 
and presented with mental retardation, microcephaly. Flanagan 
et al (5) reported 11 cases with a median age of 7 weeks (1 
day-26 weeks) at HH diagnosis and a median birth weight 
of 3.6 kg (2.8-4.35 kg) at 40 weeks gestation When Kapoor 
et al (6) studied the clinical and molecular characterisation of 
300 patients with CHH, they identified three patients who 
had HADH mutations and were diazoxide-responsive. Mean 
birth weight was -1.08 SD and mean age at presentation was 
125 days in these patients (6). Snider et al (7) investigated 
genotype and phenotype correlations in 417 children with CH 
and reported two diazoxide-responsive patients with HADH 
gene mutations. Clinical information was not provided for these 
patients. Flanagan et al (11) identified eight new diazoxide-
responsive CHH patients with a deep intronic splicing mutation 
in the HADH gene by next-generation sequencing.
All cases reported in the literature are diazoxide-responsive 
with a range in dose used from to 2-15 mg/kg/day (median 
7-8 mg/kg/day) (4,5). Comparable with other patients reported 
in the literature, our case was diazoxide-responsive with 10 
mg/kg/day at the beginning and the maintenance dose at 
older ages was 2.5-3 mg/kg/day. To identify and treat HH 
earlier is crucial for preventing persistent brain damage. Even 
for diazoxide-responsive patients, if not treated properly, the 
outcome can be dramatic like motor mental retardation, cortical 
blindness, microcephaly, etc. Due to the early diagnosis and 
proper treatment, our patient’s prognosis was very good.
The metabolic profile is heterogeneous in patients with 
HADH mutations. The first three reported patients had detectable 
urinary 3-hydroxyglutarate and raised plasma 3-hydroxybutyryl-
carnitine levels; subsequently reported cases however did not 
have abnormal urine organic acids or acylcarnitines (5). We 
could not analyse the urine organic acid profile of our patient.
Kapoor et al (10) reported a patient with CHH due 
to a HADH gene mutation, who responded to diazoxide 
but continued to have episodes of hypoglycemia even on 
diazoxide especially when taking a meal rich in protein. 
The authors described protein sensitivity in this and two 
other cases (10). A study by Heslegrave et al (17) further 
supported this finding and showed that GDH and HADH have 
a direct protein-protein interaction which is lost in patients 
with HADH gene mutations causing leucine-induced HH. A 
protein-load test has not been undertaken in our patient, but 
after a protein-rich meal, blood glucose level was detected 
as 62 mg/dL. There is almost no information about clinical 
findings of these patients with the same mutation. Only 
limited clinical findings of two siblings with the same mutation 
was published as a short report. Both has been admitted to 
hospital at 40 days of age with hypoglycemia-related seizures. 
Birth weights were normal in these patients and they were 
successfully treated with diazoxide. There is no additional 
follow-up information (15).
Although consanguinity was not reported in our family, 
most cases in the literature are known to be consanguineous. 
As the disease is recessively inherited, sequencing of HADH is 
recommended in all patients with diazoxide-responsive CHH, 
following exclusion of mutations in ABCC8/KCNJ11 genes 
(1,5), who originate from known consanguineous pedigrees, 
isolated populations or countries where inbreeding is frequent.
So far, reported mutations in the HADH gene include 
missense, nonsense, frameshift and splicing mutations, some 
small deletions and a deep intronic splicing mutation (3,6,10). 
The mutation identified in our patient was a deep intronic 
splicing mutation which was first detected by targeted next-
generation sequencing (11). This mutation has been shown 
to introduce a cryptic splice donor site which results in 
pseudoexon activation and a premature termination codon and 
was also a founder mutation in the Turkish population (11).
In the long-term follow-up period, our patient showed 
mild CHH. The prognosis was good with low-dose diazoxide 
treatment. The findings in our patient demonstrate that the 
recognition of hyperinsulinism as a cause of hypoglycemia in 
early life and early treatment can prevent neurological deficits 
especially in diazoxide-responsive forms of CHH like HADH 
deficiency.
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